Introduction
The introduction of prostate-specific membrane antigen (PSMA)-ligands was a major improvement for the diagnosis of biochemical recurrence in patients with prostate cancer, enabling better tumor detection rate compared with standard radiologic imaging procedures. 1 The clinically most validated PSMA ligand 68 Ga-PSMA-11, also called 68 Ga-PSMA-HBED-CC, presents with a very high tumor detection rate. 2 Superiority to the standard PETprobes (eg, choline derivatives) in molecular imaging was also shown. 3 Nevertheless, 68 Ga-PSMA-11 has some limitation owing to its renal elimination, as tracer accumulation in the urinary tract may reduce the diagnostic confidence in the area of the ureter or influence the detection of local recurrence after radical prostatectomy. 4 Recently PSMA-1007, a new PSMA ligand with limited renal elimination, has been introduced. 5 This tracer is labeled with Fluorine-18 and shows promising results in preliminary studies.
Case Report
The image ( Figure 1 ) shows 2 examinations of a patient with recurrent prostate cancer 5 years after diagnosis of high-risk prostate cancer (pT2c, Gleason score 8) and treatment with radical prostatectomy with subsequent prostate-specific antigen (PSA) elevation. This patient also has a history of bilateral hip arthroplasty ( Figure 1C 
Clinical Practice Points
A number of novel prostate-specific membrane antigen tracers have recently been introduced for positron emission tomography imaging of prostate cancer. This case report highlights a case of a patient with biochemical recurrence and a history of bilateral hip arthroplasty.
Diagnostic certainty of conventional morphological imaging modalities such as computed tomography and magnetic resonance imaging is limited compared with positron emission tomography in these patients owing to artifacts. 
Discussion
Cross-sectional images, such as MRI and PET/CT, are vital for accurate restaging and subsequent treatment planning in patients with prostate cancer with biochemical relapse. Unfortunately, these essential tools may be less effective in patients with arthroplasty of the hips because of image artifacts.
During the past decades, hip arthroplasty has become a common, routine treatment for patients with hip osteoarthritis. More than 950,000 total hip arthroplasty procedures were performed globally in 2010, with average rate of 131 procedures per 100,000 population. 6 It is obvious that with increasing life spans and decreased clinical threshold for surgery, these numbers will continue to rise. It is well known that MR imaging in postoperative orthopedic patients is prone to potentially severe artifacts that decrease image quality and lead to limited clinical value in these circumstances. These artefacts include intravoxel dephasing, slice thickness variation, susceptibility artifacts, diffusion-related signal loss, and inhomogeneous tissue-selective signal suppression with spectral fat-saturation techniques. [7] [8] [9] [10] In addition, all metal hardware, even if nonferromagnetic (such as titanium), can provide a locus for generation of eddy currents and hence potential heating.
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On CT images, artifacts are mainly caused by the beamhardening of polychromatic x-ray photon beams. 9, 10, 12, 13 These artifacts caused by the presence of single hip implant usually are not so severe and allow for adequate assessment of the pelvis region. But in patients with bilateral arthroplasty, the interference produced by 2 artificial hips may severely compromise the image quality and lead to the impossibility of assessing the pelvis area, in particular in patients with prostate cancer. PET/CT as a hybrid imaging technique provides not only morphologic (CT), but also functional (FDG-PET) and molecular (DOTATOC-PET or PSMA-PET) information. In recent years, PET with PSMA ligands has been proven to exhibit high diagnostic accuracy and is increasingly used in patients with suspicious recurrent prostate cancer.
68 Ga-PSMA ligands are rapidly excreted via the kidneys and are highly accumulated in the urinary bladder. It may limit the accuracy in detection of local recurrence after radical prostatectomy and regional lymph node metastases. 4, 14, 15 In contrast with this,
18
F-PSMA-1007 radioligand demonstrates limited urinary excretion, and this significantly improves the assessment of the pelvic region, 16 which can be especially important for patients with hip arthroplasty.
Conclusion
Diagnosis was achieved through PET alone, whereas MRI was not an option and CT evaluation was highly limited. 
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